Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Shire Adds To HGT Unit With Lotus Acquisition; Gets Preclinical Rare Disease Treatment

This article was originally published in The Pink Sheet Daily

Executive Summary

Shire makes a bolt-on acquisition that will complement both its rare disease franchise and its regenerative medicines unit.

You may also be interested in...



FDA Breakthrough Designation Generates Big Meetings, Big Results, Scioderm Says

Biotech start-up met with 22 agency officials to discuss development of its compound for treatment of epidermolysis bullosa, a rare, genetic connective tissue disorder.

FDA Breakthrough Designation Generates Big Meetings, Big Results, Scioderm Says

Biotech start-up met with 22 agency officials to discuss development of its compound for treatment of epidermolysis bullosa, a rare, genetic connective tissue disorder.

Spurring Innovation While Economizing On R&D Spending Remains Industry-Wide Challenge

Cash is still “cheap” but biopharma M&A continues to move slowly – mid-cap industry execs tell “The Pink Sheet” partly because there is so much competition to acquire the best assets. Meanwhile, most companies are economizing on R&D even as they strive to develop the products that will carry them into the next decade.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS074869

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel